✓Tender information last checkedLast checked 20 Oct 2026, 14:17.
Opportunity overview
The Clatterbridge Cancer Centre NHS Foundation Trust requires a Radiopharmaceuticals Service Solution to support Nuclear Medicine, PET-CT and associated diagnostic and therapeutic services. The service must include:
o Provision of a fully established cyclotron based radiopharmacy for production of labelled radioisotopes relevant for cancer diagnostics and therapy.
o Provision of a generator or cyclotron based Tc-99m radiopharmacy service.
o Provision of a radiopharmacy service capable of providing Lu-177 radiopharmaceuticals.
The service may include:
• Supply of licensed radiopharmaceuticals
• PET radiotracers
• Generators and associated consumables
• Radiopharmacy support services
• Quality assurance and regulatory compliance support
• Logistics and delivery arrangements
• Waste management and disposal
• Equipment maintenance where applicable
• Future expansion to support emerging treatments
The Trust are seeking expressions of interest and supplier feedback to inform the requirements of these services.
At this stage, anticipated contract dates are estimated only and to be confirmed as the procurement progresses.
Classification
CPV85149000 — Pharmacy services
Lots
Lot 1Value not stated
Documents and notices
Preliminary market engagement notice on Find a TenderOpen source ↗
Published notice details
Additional information from the published procurement release. Fields appear only when supplied by the source; check the original notice and tender documents before acting.
Please express your interest in this pre-market engagement by confirming your interest and emailing Emma Seed e.seed@nhs.net. Following expression of interest, we will issue a questionnaire for completion and provide further details regarding the engagement session, which may either be on MS Teams, or on-site.
Deadline for expressions of interest is 10th November 2026.
Due
10 Nov 2026, 23:59
Status
scheduled
Documents
Entry 1
Id
098948-2026
Document Type
marketEngagementNotice
Notice Type
UK2
Description
Preliminary market engagement notice on Find a Tender
1 published notice version reviewed by ProcuraAxis.
1 VERSION
1
098948-2026Preliminary market engagement notice on Find a Tender ·
PROCURAAXIS ANALYSIS
ProcuraAxis Analysis
Our approved analysis of the opportunity appears below the official tender information.
ANALYSIS PREVIEW
Opportunity intelligence at a glance
Early-stage market engagement for a radiopharmaceuticals service solution supporting Nuclear Medicine, PET-CT, and related cancer diagnostic and therapeutic services. The Trust is seeking expressions of interest and supplier feedback; this is not an open tender.
Who this may suit
Potential fit for organisations with established cyclotron-based radiopharmacy capability, Tc-99m radiopharmacy provision, and capability to provide Lu-177 radiopharmaceuticals. Optional areas may include licensed products, PET tracers, logistics, compliance support, waste, and maintenance.
Key points identified
Cyclotron-based radiopharmacyFully established cyclotron-based radiopharmacy for production of labelled radioisotopes relevant to cancer diagnostics and therapyEvidence: “Provision of a fully established cyclotron based radiopharmacy for production of labelled radioisotopes relevant for cancer diagnostics and therapy.”
Tc-99m serviceGenerator- or cyclotron-based Tc-99m radiopharmacy serviceEvidence: “Provision of a generator or cyclotron based Tc-99m radiopharmacy service.”
Lu-177 capabilityRadiopharmacy service capable of providing Lu-177 radiopharmaceuticalsEvidence: “Provision of a radiopharmacy service capable of providing Lu-177 radiopharmaceuticals.”
96% approved-analysis confidence5 supplier criteria identified2 risks or unknowns
ProcuraAxis structures information found in published procurement records, checks the result for consistency and publishes only approved analysis. Confidence describes the completeness and consistency of the available source information; it is not a guarantee of eligibility or contract award.
Early-stage market engagement for a radiopharmaceuticals service solution supporting Nuclear Medicine, PET-CT, and related cancer diagnostic and therapeutic services. The Trust is seeking expressions of interest and supplier feedback; this is not an open tender.
Who this may suit
Potential fit for organisations with established cyclotron-based radiopharmacy capability, Tc-99m radiopharmacy provision, and capability to provide Lu-177 radiopharmaceuticals. Optional areas may include licensed products, PET tracers, logistics, compliance support, waste, and maintenance.
Key deliverables
Established cyclotron-based radiopharmacy producing labelled radioisotopes for cancer diagnostics and therapy
Generator- or cyclotron-based Tc-99m radiopharmacy service
Radiopharmacy service capable of providing Lu-177 radiopharmaceuticals
SUPPLIER REQUIREMENTS
5 criteria identified
Cyclotron-based radiopharmacy
99% confidence
Fully established cyclotron-based radiopharmacy for production of labelled radioisotopes relevant to cancer diagnostics and therapy
View supporting evidence
“Provision of a fully established cyclotron based radiopharmacy for production of labelled radioisotopes relevant for cancer diagnostics and therapy.”
Tc-99m service
99% confidence
Generator- or cyclotron-based Tc-99m radiopharmacy service
View supporting evidence
“Provision of a generator or cyclotron based Tc-99m radiopharmacy service.”
Lu-177 capability
99% confidence
Radiopharmacy service capable of providing Lu-177 radiopharmaceuticals
View supporting evidence
“Provision of a radiopharmacy service capable of providing Lu-177 radiopharmaceuticals.”
Optional service elements
97% confidence
Licensed radiopharmaceuticals, PET radiotracers, generators and consumables, support services, quality/regulatory support, logistics, waste, maintenance and future expansion may be included
View supporting evidence
“The service may include:” followed by the listed elements.
Supplier eligibility criteria
99% confidence
Unknown
View supporting evidence
No eligibility, financial standing, insurance, company-size or accreditation criteria are stated in the supplied notice.
COMMERCIAL AND DELIVERY
Contract intelligence
Commercial
Contract value
99% confidence
Unknown
View supporting evidence
value_min, value_max and currency are null.
Contract dates
99% confidence
Estimated only; to be confirmed as procurement progresses
View supporting evidence
“At this stage, anticipated contract dates are estimated only and to be confirmed as the procurement progresses.”
Delivery
Service context
99% confidence
Support for Nuclear Medicine, PET-CT and associated diagnostic and therapeutic services
View supporting evidence
“requires a Radiopharmaceuticals Service Solution to support Nuclear Medicine, PET-CT and associated diagnostic and therapeutic services.”
Delivery location
98% confidence
Unknown
View supporting evidence
The supplied location is labelled “Buyer location”; it does not expressly state a service delivery location.
Logistics arrangements
98% confidence
May be included
View supporting evidence
“Logistics and delivery arrangements” is listed under “The service may include”.
PROCEDURE
How to respond
Opportunity status
99% confidence
Upcoming early-stage/planned procurement
View supporting evidence
display_status is “upcoming”; stage and source_status are “planning”.
Notice type
99% confidence
Preliminary market engagement notice on Find a Tender
View supporting evidence
notice_type: “Preliminary market engagement notice on Find a Tender”.
Current buyer request
99% confidence
Expressions of interest and supplier feedback to inform requirements
View supporting evidence
“The Trust are seeking expressions of interest and supplier feedback to inform the requirements of these services.”
Tender method and submission deadline
99% confidence
Unknown
View supporting evidence
procurement_method and procurement_method_details are null; submission_deadline is null.
RISKS AND UNKNOWNS
Points requiring attention
Early-stage scope and timetable uncertainty
99% confidence
Final requirements, contract dates, procurement route, commercial terms and submission arrangements are not yet confirmed.
View supporting evidence
The notice is a preliminary market engagement notice; “anticipated contract dates are estimated only and to be confirmed as the procurement progresses”; procurement method and deadline are null.
Optional scope uncertainty
98% confidence
Several potential components are expressly optional rather than confirmed requirements.
View supporting evidence
The notice states “The service may include” before licensed radiopharmaceuticals, PET tracers, consumables, support, logistics, waste and maintenance.
ProcuraAxis analysis supplements, but does not replace, the original notice and tender documents. Always verify eligibility, deadlines and commercial terms with the issuing authority.
Continue in your ProcuraAxis workspaceFree account · Full approved analysis